Claim Amendments:

1. (Currently amended) A compound of formula:



(I)

in which:

- A represents a group chosen from the following:

$^{-}C{\equiv}C^{-}$; $^{-}CH{=}CH^{-}$, $^{-}CH_2{-}CH_2{-}$

- n is equal to 1 or 2;

- X represents a hydrogen, chlorine or fluorine atom or a methyl or methoxy group;

- Y represents a hydrogen atom or a chlorine or fluorine atom;

- R_1 represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a phenyl group monosubstituted or disubstituted with a fluorine or chlorine atom or with a (C_1-C_3)alkoxy or trifluoromethyl group; a cycloheptyl, *tert*-butyl, dicyclopropylmethyl, bicyclo[3.2.1]octanyl, 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl or 1- or 2-adamantyl group; or R_1 represents a phenyl group, it being understood that, in this case, X or Y is other than hydrogen; or R_1 represents a cyclohexyl group, it being understood that, in this case, X and Y are other than hydrogen;

- R_2 and R_3 form, with the nitrogen atom to which they are bonded, a ~~5- to 8-membered~~ 7-membered amine ring; ~~a morpholinyl group optionally substituted in positions 3 and 5 with a methyl; or a 4-phenyl-1,2,3,6-tetrahydropyridyl group optionally substituted on the phenyl with a halogen or a trifluoromethyl, (C_1-C_4)alkyl or (C_1-C_4)alkoxy group;~~

and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.

2. (Currently amended) A compound according to Claim 1 in which:

- A represents a group chosen from the following:

$^{-}C{\equiv}C^{-}$; $^{-}CH{=}CH^{-}$; $-CH_2-CH_2-$

- n is equal to 1;

- X represents a hydrogen or chlorine atom or a methyl group;

- Y represents a hydrogen or chlorine atom;

- R_1 represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a phenyl group monosubstituted or disubstituted with a fluorine or chlorine atom or with a methoxy or trifluoromethyl group; a *tert*-butyl or 1- or 2-adamantyl group; or R_1 represents a phenyl group, it being understood that, in this case, X and Y are other than hydrogen; or else R_1 represents a cyclohexyl group, it being understood that, in this case, X and Y are other than hydrogen;

- R_2 and R_3 form, with the nitrogen atom to which they are bonded, a ~~6- to 8-membered~~ 7-membered amine ring;

and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.

3. (Currently amended) A compound according to Claim 2 of formula:



(I.1)

in which:

- A represents a group chosen from the following:

$^{-}C{\equiv}C^{-}$; $^{-}CH{=}CH^{-}$; $^{-}CH_2{-}CH_2{-}$

- X represents a hydrogen or chlorine atom;

- Y represents a hydrogen atom or a chlorine atom;

- R_1 represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a phenyl group mono- or disubstituted with a fluorine or chlorine atom or a methoxy group; a *tert*-butyl or 1- or 2-adamantyl group; or R_1 represents a cyclohexyl or phenyl group, it being understood that, in this case, X and Y are other than hydrogen;

and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.

4. (Previously presented) A compound according to Claim 3 in which A represents the $^{-}CH=CH^{-}$ group, in particular of (Z) configuration.

5. (Previously presented) A compound according to Claim 4 in which X represents a chlorine atom and Y represents a hydrogen atom.

6. (Previously presented) A compound according to Claim 5 in which R_1 represents a phenyl group monosubstituted or disubstituted with a fluorine or chlorine atom or a methoxy group, and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.

7. (Previously presented) A compound:

- 1-[(Z)-3-(2-chloro-3'-fluorobiphenyl-4-yl)propen-2-yl]azepane;
- 1-[(Z)-3-(2-chloro-3'-5'-difluorobiphenyl-4-yl)propen-2-yl]azepane;
- 1-[(Z)-3-(2-chloro-3'-methoxybiphenyl-4-yl)propen-2-yl]azepane;

according to Claim 1, as well as the salts with pharmaceutically acceptable acids, solvates and hydrates thereof.

8. (Previously presented) A compound 1-[(Z)-3-(2-chloro-3'-methoxybiphenyl-4-yl)propen-2-yl]azepane according to Claim 1, as well as the salts with pharmaceutically acceptable acids, solvates and hydrates thereof.

9. (Currently amended) A method for preparing a compound <u>of formula:</u>



(I)

according to Claim 1 in which A represents a $^{-}C\equiv C^{-}$ group, wherein:

a) either, if n = 1, a Mannich reaction is carried out between the phenylacetylene derivative of formula:



(II)

in which R_1, X and Y are as defined for (I), the formaldehyde and the amine (1) HNR_2R_3, R_2 and R_3 being as defined for (I);

b) or a Suzuki coupling is carried out between the compound of formula:



(Ia)

in which X, Y, n, R_2 and R_3 are as defined for (I) and Z represents a bromine, an iodine or a trifluoromethanesulphonate (OTf) group, and a boron derivative (2) of formula R_1-$B(OR)_2$ in which R_1 is as defined for (I) and R represents a hydrogen atom, an alkyl or aryl group in the presence of a base and a metal catalyst;

c) or, when R_1 represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a cycloheptyl, 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl or adamantyl group, a coupling is carried out between the compound (Ia) in which Z represents an iodine or bromine atom and the ketone (3) corresponding to R_1 represented by 

in the presence of a base, to give the intermediate compound of formula:



(I')

in which X, Y, n, R_2 and R_3 are as defined for (I); said compound (I') then being reduced under selective conditions;

d) or a coupling reaction is carried out between the amine of formula:



(4)

in which n, R_2 and R_3 are as defined for (I), and the compound of formula:



(III)

in which R_1, X and Y are as defined for (I) and Z represents a bromine or iodine atom or a trifluoromethylsulphonate (triflate or OTf) group.

10. (Currently amended) A method for preparing a compound of formula:



(I)

according to Claim 1 in which A represents a $^{-}CH=CH^{-}$ group wherein a hydrogenation with nascent hydrogen or in the presence of cyclohexene is carried out on compound (I) in which A represents an acetylene group $^{-}C\equiv C^{-}$, in order to prepare the ethylenic compound (I) in the form of a mixture of the Z and E isomers, or this hydrogenation is carried out in the presence of a metal catalyst on a support in order to prepare the ethylenic compound (I) in Z form, or alternatively compound (I) in which A represents an acetylene group $^{-}C\equiv C^{-}$ is reacted with a metal hydride in order to prepare the ethylenic compound (I) in E form.

11. (Currently amended) A method for preparing a compound of formula:



(I)

according to Claim 1 in which A represents a $-CH_2-CH_2-$ group wherein a hydrogenation is carried out on compound (I) in which A represents a $^{-}CH=CH^{-}$ or $^{-}C\equiv C^{-}$ group.

12. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 1.

13. (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment and effective amount of a compound according to Claim 1.

14. (Cancelled)

15. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 2.

16. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 3.

17. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 4.

18. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 5.

19. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 6.

20. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 7.

21. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 8.

22 (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 2.

23. (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 3.

24. (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 4.

25. (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 5.

26. (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 6.

27. (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 7.

28. (Currently amended) A method for treating ~~psychotic disorders~~ the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 8.

29 - 35 (Cancelled)